Skip to main content
    S

    Surrozen Inc (SRZN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $23.75
    +0.24 (+1.02%)

    Market Cap: $279.15M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(10/20)
    Avg Surprise
    -41.80%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.32
    Range$-1.33 - $-1.30
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.29-1.9%
    60d ago$-1.29-1.9%
    30d ago$-1.320.0%
    7d ago$-1.320.0%
    Current$-1.32
    Revenue Consensus
    $380000
    Range$0 - $1M
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-5.84
    Range$-5.84 - $-5.84
    1 analysts
    Revenue Consensus
    $5M
    Range$5M - $7M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-5.84---
    Sep 26EST
    		-$-1.32---
    Jun 26
    Reported Aug 6
    		$-0.41N/A+69.40%Beat+64.0%
    Mar 26
    Reported May 6
    		$-4.63$-0.72-543.06%Miss-158.5%
    Dec 25
    Reported Mar 23
    		$-9.62$-1.24-678.79%Miss-5.8%
    Sep 25
    Reported Nov 7
    		$-3.60$-1.17-207.69%Miss-718.2%
    Jun 25
    Reported Aug 8
    		$-1.14$-1.23+7.32%Beat+85.7%
    Mar 25
    Reported May 9
    		$7.92$-1.09+826.61%Beat+286.8%
    Dec 24
    Reported Mar 31
    		$-9.09$-2.70-236.67%Miss-106.1%
    Sep 24
    Reported Nov 6
    		$-0.44N/A+84.12%Beat+91.4%
    Jun 24
    Reported Aug 12
    		$-7.99$-2.79-186.38%Miss-71.8%
    Mar 24
    Reported May 8
    		$-4.24$-4.25+0.24%Beat+41.1%
    Dec 23
    Reported Mar 27
    		$-4.41$-3.00-47.00%Miss-14600.0%
    Sep 23
    Reported Nov 8
    		$-5.10$-4.20-21.43%Miss+10.5%
    Jun 23
    Reported Aug 9
    		$-4.65$-6.00+22.50%Beat+22.5%
    Mar 23
    Reported May 10
    		$-7.20$-5.42-32.84%Miss-108.7%
    Dec 22
    Reported Mar 22
    		$-0.03N/A+93.02%Beat+95.0%
    Sep 22
    Reported Nov 14
    		$-5.70$-6.43+11.35%Beat+25.5%
    Jun 22
    Reported Aug 11
    		$-6.00$-6.90+13.04%Beat-1478.9%
    Mar 22
    Reported May 11
    		$-3.45N/A+57.41%Beat-1012.9%
    Dec 21
    Reported Mar 24
    		$-0.60$-0.44-36.36%Miss-
    Sep 21
    Reported Nov 15
    		$-7.65$-5.85-30.77%Miss-
    Jun 21
    Reported Jul 15
    		$-0.38N/AN/ABeat-
    Mar 21
    Reported May 14
    		$-0.31N/AN/ABeat-
    Dec 20
    Reported Jan 4
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-1.30EV/EBITDAN/A
    Price/FCF-7.92xFCF Yield-12.63%
    Profitability
    Profit Margin0.00%Operating Margin-207.40%
    ROE-62.80%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio12.14xQuick Ratio12.14x
    Trading Statistics
    Beta0.47Avg Volume1.09M
    52-Week High$37.8352-Week Low$11.39

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$26.96
    SMA 20$25.52
    SMA 50$23.64
    SMA 200$24.71
    EMA 10$26.00
    EMA 20$25.54
    EMA 50$24.28
    EMA 200$22.88

    MACD

    Line: 0.87Signal: 1.43Hist: -0.56

    ADX

    ADX: 35.8+DI: 29.5-DI: 23.1

    Aroon & PSAR

    Aroon Up48.0
    Aroon Down40.0
    PSAR$36.90

    Bollinger Bands

    Upper Band$37.23
    Lower Band$13.82
    %B Position9171%(Upper)
    Band Width0.42

    RSI (14-Day)

    Neutral
    47.2

    Momentum Oscillators

    Stoch %K20.7
    Stoch %D36.8
    Williams %R-88.1
    ROC (10d)-26.2%
    Momentum-8.43
    CCI (20d)-26.8
    MFI (14d)38.3

    Volatility Measures

    ATR (14d)$3.15(13.3%)
    StdDev (20d)5.85
    Hist Vol406.2%(High)

    Volume Flow

    VWAP$23.71
    OBV13.1M
    AD Line2.2M
    CMF (20d)0.065

    Volume Metrics

    Avg Vol (20d)1.2M
    Vol Ratio0.5x
    VWMA (20d)$30.47

    Pivot Points

    R3$27.16
    R2$25.76
    R1$24.64
    Pivot Point$23.24
    S1$22.12
    S2$20.72
    S3$19.60

    Advanced Oscillators

    TSI7.55
    Ultimate Osc44.8
    KST323.17

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$5.00M$5.00M$528,000$983,000$983,000$983,000$655,000$10.00M$0$0$0$0
    Cost of Revenue$0$0$45,000$0$0$0$322,000$0$0$0N/A$0
    Gross Profit$5.00M$5.00M$528,000$983,000$983,000$983,000$655,000$10.00M$0$0N/A$0
    Operating Expenses$15.37M$15.46M$13.17M$11.87M$10.00M$10.53M$9.25M$8.77M$9.05M$9.13M$9.72M$11.19M
    R&D$8.48M$9.33M$8.99M$7.77M$6.04M$6.56M$5.35M$5.20M$5.33M$5.25M$6.09M$6.11M
    SG&A$6.89M$6.13M$4.18M$4.09M$3.96M$3.98M$3.90M$3.57M$3.71M$3.88M$3.59M$3.57M
    Operating Income$-10,370,000$-10,456,000$-12,639,000$-10,885,000$-9,017,000$-9,551,000$-8,592,000$1.23M$-9,049,000$-9,130,000$-9,724,000$-11,189,000
    Interest Income$938,000$912,000$788,000$911,000$1.02M$296,000$387,000$431,000$490,000$385,000$509,000$661,000
    Interest Expense$0$40.19M$18.06M$60.76M$0$34.88M$20.52M$2.67M$0$0$0$0
    Income Before Tax$10.93M$-50,650,000$-30,697,000$-71,643,000$8.23M$-44,427,000$-29,115,000$-1,434,000$-4,864,000$-8,830,000$-9,311,000$-10,445,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$50.18M$-127,505,000$-183,159,000$-71,643,000$39.75M$-26,970,000$-48,436,000$-1,434,000$-4,864,000$-8,830,000$-8,913,000$-10,445,000
    EBITDA$10.04M$-51,497,000$-31,440,000$-72,493,000$7.34M$-44,429,000$-29,180,000$-1,523,000$-4,968,000$-8,466,000$-9,413,000$-10,831,000
    EBIT$9.99M$-51,562,000$-31,485,000$-72,554,000$7.20M$-44,723,000$-29,502,000$-1,865,000$-5,354,000$-9,215,000$-9,820,000$-11,106,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SRZN

    News

    Top Biotech Stock: Guggenheim Names Surrozen as Best Pick

    Guggenheim Securities has named Surrozen, Inc. as its top biotechnology stock pick, initiating coverage with a Buy rating and a $42.00 price target. The firm believes Surrozen is significantly undervalued and highlights...

    Yahoo! Finance Canada•10/15/26•Bullish

    Understanding the Setup: (SRZN) and Scalable Risk

    Surrozen Inc. (NASDAQ: SRZN) is showing weak near and mid-term sentiment despite a positive long-term outlook. An exceptional short setup is identified with a high risk-reward ratio...

    Stock Traders Daily•10/15/26•Somewhat-Bearish

    FDA clears Surrozen's IND for for DME therapy

    Surrozen, Inc. has received FDA clearance for its investigational new drug (IND) application for SZN-8141, a bifunctional antibody for treating diabetic macular edema (DME) and wet age-related macular degeneration (AMD)....

    Glance by Eyes On Eyecare•10/15/26•Bullish

    Why Did Surrozen (NASDAQ:SRZN) Fall 11.3% After Its Gainers Run?

    Surrozen (NASDAQ:SRZN) experienced an 11.3% decline on October 13, 2026, trading on light volume, with no apparent catalyst or company news. This drop partially retraces a 11.2% gain from October 8...

    kalkine.ca•10/13/26•Somewhat-Bearish

    Surrozen, Inc. Common Stock (SRZN) Stock Price: Oct 7 Close $25.15

    This article provides an overview of Surrozen, Inc. (SRZN) stock as of October 7, 2026, with a closing price of $25.15. It details key financial fundamentals, recent news, technical indicators, and analyst ratings...

    Gotrade•10/8/26•Somewhat-Bullish

    SRZN Valuation and Fair Value

    P/E
    -1.3x
    P/FCF
    -7.9x
    P/B
    -1.3x
    See GNG's fair value

    SRZN Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -207.4%
    Net margin
    0.0%
    ROE
    -62.8%
    FCF margin
    -303.9%
    FCF yield
    -12.6%

    SRZN Competitors

    CompanyTicker
    Fulcrum Therapeutics IncFULC
    Anika Therapeutics IncANIK
    Ocugen IncOCGN
    InfuSystems Holdings IncINFU
    Movano IncMOVE
    Treace Medical Concepts IncTMCI
    QuantumSi IncQSI
    Nautilus Biotechnology IncNAUT

    Sector: Healthcare

    SRZN Analyst Ratings

    Consensus
    Buy
    Analysts
    6
    Strong Buy
    0
    Buy
    6
    Hold
    0
    Sell
    0
    Strong Sell
    0

    SRZN Bull Case vs Bear Case

    Bull case

    • SRZN grew quarterly revenue 408.6% year over year.
    • 100.0% of SRZN's analyst ratings are Buy or Strong Buy.

    SRZN Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -84.8%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.32
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 2 down

    Frequently Asked Questions About SRZN

    Does SRZN pay dividends?

    Surrozen Inc (SRZN) does not currently pay a regular dividend.

    What is SRZN's market cap?

    Surrozen Inc (SRZN) has a market capitalization of $279.15M with a current stock price of $23.75.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In